Building healthier futures powered by thoughtful science

We are a highly focused, research-driven biopharmaceutical company working in rare diseases. We're exploring the potential of cutting-edge science as a subsidiary of Nippon Shinyaku Co., Ltd. In Japan.

Advancing rare disease research

Inspired by our own families, as well as the individuals we aim to provide with treatment, NS Pharma is conducting advanced research in rare diseases, including exon-skipping technology, to offer new, effective treatment options for Duchenne. We’re also developing JAK1 inhibition for the potential treatment of eosinophilic granulomatosis with polyangiitis (EGPA).

Therapeutic areas

NS Pharma is working to have an important impact on the lives of patients with rare diseases. Our therapeutic areas encompass neurological diseases and inflammatory diseases.

Scientific approaches

Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell therapy and JAK1 inhibition technology.

Therapeutic areas

NS Pharma is working to have an important impact on the lives of patients with rare diseases. Our therapeutic areas encompass neurological diseases and inflammatory diseases.

Scientific approaches

Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell therapy and JAK1 inhibition technology.

From our blog

Press Release / March 27, 2025

Positive Data Showing Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Released at 2025 MDA Conference

Press Release / March 6, 2025

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

News / February 7, 2025

NS Pharma and MiNA Therapeutics: Meeting Unmet Medical Needs Through Partnership and Co-creation

Press Release / March 27, 2025

Positive Data Showing Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Released at 2025 MDA Conference

Press Release / March 6, 2025

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

News / February 7, 2025

NS Pharma and MiNA Therapeutics: Meeting Unmet Medical Needs Through Partnership and Co-creation

Social media

Exciting news for the #DuchenneCommunity!💡🎉

We're thrilled to share the latest results from the HOPE-2 clinical trial, showing promising long-term efficacy of #Deramiocel in treating #Duchenne muscular dystrophy cardiomyopathy.

Read the press release: https://ow.ly/bMEa50VpPK7 https://x.com/NSPharmaInc/status/1905286589363691924/photo/1

Say hello to Tara Gorombey, our new Manager of Human Resources! 🎉

With 15+ years of experience, she brings a deep expertise in recruiting for rare diseases and specialized healthcare roles.

Outside of work, Tara enjoys gardening, reading & hiking!

#NewHire #GrowingTeam https://x.com/NSPharmaInc/status/1904896246097002941/photo/1

We're proud to be sponsoring the #PPMDTogether event this weekend in Minneapolis!

After its incredible success last year, it's back March 28-29- and we’re thrilled to be part of it.

If you're attending, be sure to stop by and say hello!

Learn more: https://ow.ly/qQEG50Vnk01 https://x.com/NSPharmaInc/status/1904186953664495835/photo/1

We're en route to New Orleans!

NS Pharma is proud to sponsor another upcoming #Community dinner session hosted by @CureDuchenne, this time in Louisiana!

It's a great opportunity to connect with your community.

Register here: https://ow.ly/Rw0350VkARw

#Duchenne #DMD https://x.com/NSPharmaInc/status/1903099291687620883/photo/1

The NSP team had an incredible time at the #MDAConference, connecting with experts, advocates, and families who share our commitment to the neuromuscular community.

Thank you to everyone who stopped by to chat with us! Until next time!

#DuchenneCommunity #StrongerTogether https://x.com/NSPharmaInc/status/1902404616454635884/photo/1

4

We’re excited to introduce Max as the newest member of our Commercial Operations team, joining us as a Commercial Data & Reporting Analyst!🎉

Welcome to the team, Max!👏

#NewHire https://x.com/NSPharmaInc/status/1901635019619139884/photo/1

The 2025 @MDAorg Conference is just around the corner and we can't wait to get involved!

Our team will be in Dallas from March 16th-19th so be sure to stop by booth #639 to say hello!

#Duchenne #Neuromuscular #DMD https://x.com/NSPharmaInc/status/1899837790914842883/photo/1